Previous 10 | Next 10 |
Rani Therapeutics press release (NASDAQ:RANI): Q4 GAAP EPS of -$0.27 misses by $0.04. Cash and cash equivalents $117.45M For further details see: Rani Therapeutics GAAP EPS of -$0.27 misses by $0.04
- Initiated a Phase 1 clinical trial of RT-102 for the potential treatment of osteoporosis - - Unveiled the high-capacity RaniPill ™ HC , capable of delivering payloads of up to 20 mg - - Strengthened Board with the appointments of Lyn Baranowski and Lisa ...
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced that the company will release...
Rani Therapeutics (NASDAQ:RANI) began a phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34), to treat osteoporosis, delivered via RaniPill capsule. Osteoporosis is a disorder that causes bones to become weak and brittle. PTH is one of the treatm...
SAN JOSE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 s...
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - ...
SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Romett...
Rani Therapeutics (NASDAQ:RANI): Q3 GAAP EPS of -$0.16 beats by $0.02. Cash and cash equivalents of $129.74M Press Release For further details see: Rani Therapeutics EPS beats by $0.02
SAN JOSE, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quart...
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) traded today at a new 52-week high of $36.00. This new high was reached on above average trading volume as 881,000 shares traded hands, while the average 30-day volume is approximately 65,000 shares. Rani Therapeutics Holdings Inc. (NASDAQ:RA...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a...
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...